Publications

2025

5. A rare case of 45X/46XY mosaic Turner syndrome in a neonateGarg A, Hittelman A, Lepore C, Gujral J, Derar N, Vash-Margita A. 5. A rare case of 45X/46XY mosaic Turner syndrome in a neonate. Journal Of Pediatric And Adolescent Gynecology 2025, 38: 232. DOI: 10.1016/j.jpag.2025.01.038.
Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial.Kinnaird A, Luger F, Cash H, Ghai S, Urdaneta-Salegui LF, Pavlovich CP, Brito J, Shore ND, Struck JP, Schostak M, Harland N, Rodriguez-Socarrás M, Brisbane WG, Lughezzani G, Toledano H, Ouertani MS, Macek P, Fung C, Tu W, Gusenleitner A, Günzel K, Incze PF, George AK, Pereira JG, Jansen R, Renzulli J 2nd, Klotz L, OPTIMUM Investigators. Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial. JAMA 2025 PMID: 40121537, DOI: 10.1001/jama.2025.3579.
Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial.Kinnaird A, Luger F, Cash H, Ghai S, Urdaneta-Salegui LF, Pavlovich CP, Brito J, Shore ND, Struck JP, Schostak M, Harland N, Rodriguez-Socarrás M, Brisbane WG, Lughezzani G, Toledano H, Ouertani MS, Macek P, Fung C, Tu W, Gusenleitner A, Günzel K, Incze PF, George AK, Pereira JG, Jansen R, Renzulli J 2nd, Klotz L, OPTIMUM Investigators. Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial. JAMA 2025 PMID: 40121537, DOI: 10.1001/jama.2025.3579.
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, jco2402219. PMID: 40048689, DOI: 10.1200/jco-24-02219.
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.Petrylak D, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, Todenhöfer T, Gurney H, Kramer G, Bergman A, Zalewski P, De Santis M, Armstrong A, Gerritsen W, Pachynski R, Byun S, Retz M, Levesque E, McDermott R, Bracarda S, Manneh R, Levartovsky M, Li X, Schloss C, Poehlein C, Fizazi K. Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial. Journal Of Clinical Oncology 2025, jco2401283. PMID: 40043230, DOI: 10.1200/jco-24-01283.
IMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDYAnnapureddy D, Taylor J, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, O'Donnell M, Kamat A, Woldu S, Lotan Y. IMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDY. Urologic Oncology Seminars And Original Investigations 2025, 43: 81. DOI: 10.1016/j.urolonc.2024.12.204.
IMPROVED OUTCOMES IN BCG-UNRESPONSIVE BLADDER CANCER PATIENTS WITH NON-INVASIVE DISEASE UNDERGOING BLADDER SPARING THERAPY COMPARED TO T1 DISEASE: RESULTS FROM AN INTERNATIONAL COHORTAnnapureddy D, Taylor J, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, O'Donnell M, Kamat A, Woldu S, Lotan Y. IMPROVED OUTCOMES IN BCG-UNRESPONSIVE BLADDER CANCER PATIENTS WITH NON-INVASIVE DISEASE UNDERGOING BLADDER SPARING THERAPY COMPARED TO T1 DISEASE: RESULTS FROM AN INTERNATIONAL COHORT. Urologic Oncology Seminars And Original Investigations 2025, 43: 80-81. DOI: 10.1016/j.urolonc.2024.12.203.
340 Cytomorphologic Challenges in Cervical Pap Tests of Transgender Men on Androgen Therapy: A Cyto-Histological Correlation StudyHaque M, Amraei R, Iyer K, Krishnamurti U, Adeniran A, Sun T. 340 Cytomorphologic Challenges in Cervical Pap Tests of Transgender Men on Androgen Therapy: A Cyto-Histological Correlation Study. Laboratory Investigation 2025, 105: 102567. DOI: 10.1016/j.labinv.2024.102567.
315 Clinicopathologic Characteristics of Thyroid Nodules with THADA-IGF2BP3 Fusion Identified on Fine Needle AspirationBernhisel A, Sun T, Prasad M, Ladenheim A, Cai G, Adeniran A. 315 Clinicopathologic Characteristics of Thyroid Nodules with THADA-IGF2BP3 Fusion Identified on Fine Needle Aspiration. Laboratory Investigation 2025, 105: 102542. DOI: 10.1016/j.labinv.2024.102542.
411 Correlation of ACR-TI-RADS, Cytology, Histology, and Molecular studiesYu S, Wang M, Langdon J, Sinard J, Cai G, Prasad M, Adeniran A. 411 Correlation of ACR-TI-RADS, Cytology, Histology, and Molecular studies. Laboratory Investigation 2025, 105: 102638. DOI: 10.1016/j.labinv.2024.102638.
Abstract No. 192 AI-Assisted Prostate Segmentation Module for MRI-Guided Transurethral Ultrasound (TULSA) Treatment Planning: Multi-reader Multi-case Study and Initial Real-World ExperienceRaman S, Arora S, Ghanouni P, Oto A, Moin A, Karamanian A, Sprenkle P, Klotz L, Pavlovich C, Leung B, Wright C, Steiner E, Princenthal R. Abstract No. 192 AI-Assisted Prostate Segmentation Module for MRI-Guided Transurethral Ultrasound (TULSA) Treatment Planning: Multi-reader Multi-case Study and Initial Real-World Experience. Journal Of Vascular And Interventional Radiology 2025, 36: s88-s89. DOI: 10.1016/j.jvir.2024.12.238.
CAPTAIN RANDOMIZED CONTROLLED TRIAL OF TULSA AGAINST RADICAL PROSTATECTOMY FOR INTERMEDIATE-RISK PROSTATE CANCER: DESIGN AND RECRUITMENT UPDATEMeng X, Lotan Y, Kella N, Koch M, Pavlovich C, George A, Michel K, Sprenkle P, Sonn G, Mynderse L, Anttinen M, Chin J, Inman B, Mehan R, Banapour P, Sharif-Afshar A, Woodrum D, Ghanouni P, Arora S, Macura K, Princenthal R, Cohen M, Staruch R, Clarke G, Costa D, Klotz L. CAPTAIN RANDOMIZED CONTROLLED TRIAL OF TULSA AGAINST RADICAL PROSTATECTOMY FOR INTERMEDIATE-RISK PROSTATE CANCER: DESIGN AND RECRUITMENT UPDATE. Urologic Oncology Seminars And Original Investigations 2025, 43: 79. DOI: 10.1016/j.urolonc.2024.12.200.
401 Prognostic Value of Pelvic Washing Cytology in Early-Stage Endometrial Cancer: A 10-Year Single-Institute Cohort StudyWang M, Abi-Raad R, Krishnamurti U, Cai G, Adeniran A, Sun T. 401 Prognostic Value of Pelvic Washing Cytology in Early-Stage Endometrial Cancer: A 10-Year Single-Institute Cohort Study. Laboratory Investigation 2025, 105: 102628. DOI: 10.1016/j.labinv.2024.102628.
351 Follicular Neoplasms: Cytomorphological Subclassification, Molecular Alterations and Risk of MalignancyKaur H, Gereg C, Abi-Raad R, Adeniran A, Cai G. 351 Follicular Neoplasms: Cytomorphological Subclassification, Molecular Alterations and Risk of Malignancy. Laboratory Investigation 2025, 105: 102578. DOI: 10.1016/j.labinv.2024.102578.
DEVELOPMENT OF EX VIVO PATIENT-DERIVED MODELS TO UNCOVER THE TUMOR-IMMUNE MICROENVIRONMENT IN RENAL CELL CARCINOMAKashima S, Gupta R, Moritz V, Sadak K, Walker J, Adeniran A, Humphrey P, Dinulescu D, Palmer D, Hammond S, Bosenberg M, Hurwitz M, Kenney P, Braun D. DEVELOPMENT OF EX VIVO PATIENT-DERIVED MODELS TO UNCOVER THE TUMOR-IMMUNE MICROENVIRONMENT IN RENAL CELL CARCINOMA. Urologic Oncology Seminars And Original Investigations 2025, 43: 22-23. DOI: 10.1016/j.urolonc.2024.12.057.
831 AXL Receptor Tyrosine Kinase Expression in Metastatic Renal Cell Carcinoma: Insights from the METEOR trialLaimon Y, Paul M, Jammihal T, Ghandour F, Ahmar N, Simsek B, Matar S, Denize T, Mohanna R, De Oliveira G, Delcea A, Shukla S, Braun D, Sun M, Aftab D, Saad E, Machaalani M, Xie W, Choueiri T, Signoretti S. 831 AXL Receptor Tyrosine Kinase Expression in Metastatic Renal Cell Carcinoma: Insights from the METEOR trial. Laboratory Investigation 2025, 105: 103064. DOI: 10.1016/j.labinv.2024.103064.
796 Tertiary Lymphoid Structures Predict Response to First-Line Nivolumab Therapy in Advanced Renal Cell Carcinoma: Findings from the HCRN GU16-260 Clinical TrialAhmar N, Simsek B, Jegede O, Matar S, Savla V, Laimon Y, Mohanna R, De Oliveira G, Sheshdeh A, Delcea A, Paul M, Choueiri T, Xie W, Freeman G, Braun D, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Wu C, McDermott D, Atkins M, Signoretti S. 796 Tertiary Lymphoid Structures Predict Response to First-Line Nivolumab Therapy in Advanced Renal Cell Carcinoma: Findings from the HCRN GU16-260 Clinical Trial. Laboratory Investigation 2025, 105: 103029. DOI: 10.1016/j.labinv.2024.103029.
EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIESRahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES. Urologic Oncology Seminars And Original Investigations 2025, 43: 43. DOI: 10.1016/j.urolonc.2024.12.109.
HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapyJiang Q, Braun D, Clauser K, Ramesh V, Shirole N, Duke-Cohan J, Nabilsi N, Kramer N, Forman C, Lippincott I, Klaeger S, Phulphagar K, Chea V, Kim N, Vanasse A, Saad E, Parsons T, Carr-Reynolds M, Carulli I, Pinjusic K, Jiang Y, Li R, Syamala S, Rachimi S, Verzani E, Stevens J, Lane W, Camp S, Meli K, Pappalardi M, Herbert Z, Qiu X, Cejas P, Long H, Shukla S, Van Allen E, Choueiri T, Churchman L, Abelin J, Gurer C, MacBeath G, Childs R, Carr S, Keskin D, Wu C, Kaelin W. HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy. Cell 2025 PMID: 40023154, DOI: 10.1016/j.cell.2025.01.046.
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma.Hugaboom M, Wirth L, Street K, Ruthen N, Jegede O, Schindler N, Shah V, Zaemes J, El Ahmar N, Matar S, Savla V, Choueiri T, Denize T, West D, McDermott D, Plimack E, Sosman J, Haas N, Stein M, Alter R, Bilen M, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C, Braun D. Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma. Cancer Discovery 2025, of1-of21. PMID: 39992403, DOI: 10.1158/2159-8290.cd-24-0991.
Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder CancerSmani S, DuBois J, Zhao K, Sutherland R, Rahman S, Humphrey P, Hesse D, Tan W, Martin D, Lokeshwar S, Ghali F. Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer. Current Oncology Reports 2025, 1-11. PMID: 39976835, DOI: 10.1007/s11912-025-01645-7.
Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study.Dizman N, Doshi S, Knezevic A, Feinaj A, Sayegh N, Hobeika C, Alaghehbandan R, Rives H, Zengin Z, Braun D, Zibelman M, McGregor B, Hammers H, Ged Y, Ornstein M, Msaouel P, Hahn A, Voss M. Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study. Journal Of Clinical Oncology 2025, 43: 503-503. DOI: 10.1200/jco.2025.43.5_suppl.503.
Survival of patients with metastatic renal cell carcinoma with or without brain metastases.Hurwitz M, Considine B, Hasson N, Savion Gaiger N, Nelson M, Chiang V, Kluger H, Braun D, Schoenfeld D, Sznol M, Leapman M. Survival of patients with metastatic renal cell carcinoma with or without brain metastases. Journal Of Clinical Oncology 2025, 43: 476-476. DOI: 10.1200/jco.2025.43.5_suppl.476.
A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC).Saad E, El Ahmar N, Simsek B, Jegede O, Matar S, Mohanna R, Yekeduz E, McDermott D, Plimack E, Sosman J, Haas N, Hurwitz M, Hammers H, Van Allen E, Choueiri T, Atkins M, Signoretti S, Braun D. A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2025, 43: 591-591. DOI: 10.1200/jco.2025.43.5_suppl.591.
INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC).Motzer R, Braun D, Powles T, Gurney H, Fong L, George D, Haas N, McDermott D, Shuch B, Meehan R, Posadas T, Wu S, Elfiky A, Choueiri T. INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC). Journal Of Clinical Oncology 2025, 43: tps610-tps610. DOI: 10.1200/jco.2025.43.5_suppl.tps610.
Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): Long-term outcomes from JAVELIN Bladder 100.Gupta S, Grivas P, Park S, Petrylak D, Tyroller K, Hoffman J, Bellmunt J. Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): Long-term outcomes from JAVELIN Bladder 100. Journal Of Clinical Oncology 2025, 43: 869-869. DOI: 10.1200/jco.2025.43.5_suppl.869.
A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.Sadeghi S, Callis S, Lara P, Berg S, Brown J, Bangs R, Nakagawa D, Daneshmand S, Ian Murchie Jr., Flaig T, Petrylak D, Lerner S. A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design. Journal Of Clinical Oncology 2025, 43: tps887-tps887. DOI: 10.1200/jco.2025.43.5_suppl.tps887.
Modeling survival outcomes of KEYNOTE-564 with standard of care control arm treatment: A simulation study.Ghali F, Rahman S, James S. Modeling survival outcomes of KEYNOTE-564 with standard of care control arm treatment: A simulation study. Journal Of Clinical Oncology 2025, 43: 517-517. DOI: 10.1200/jco.2025.43.5_suppl.517.
Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.Albiges L, Motzer R, Trevino S, Kanesvaran R, Centkowski P, Reimers M, Sade J, Pouessel D, Biscaldi E, Esteban E, Arranz Arija J, Tykodi S, Ma H, Zhou L, Van Kooten Losio M, Simmons A, Rangwala F, Braun D, Choueiri T, Powles T. Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313. Journal Of Clinical Oncology 2025, 43: 438-438. DOI: 10.1200/jco.2025.43.5_suppl.438.
Comprehensive proteomic profiling of plasma samples associated with response or resistance to immune checkpoint inhibitors (ICI) in patients with renal cell carcinoma (RCC).Kashima S, Xu W, Canniff J, Saliby R, Sun M, Lee G, Machaalani M, Signoretti S, McGregor B, McKay R, Choueiri T, Braun D. Comprehensive proteomic profiling of plasma samples associated with response or resistance to immune checkpoint inhibitors (ICI) in patients with renal cell carcinoma (RCC). Journal Of Clinical Oncology 2025, 43: 562-562. DOI: 10.1200/jco.2025.43.5_suppl.562.
Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.Saliby R, Labaki C, Jammihal T, Soulati H, Gallegos J, Peris A, McCurry D, Shah V, Poduval D, El Zarif T, El Ahmar N, Nabil Laimon Y, Bagheri Sheshdeh A, Eid M, Krajewski K, Signoretti S, Van Allen E, Shukla S, Choueiri T, Braun D. Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Journal Of Clinical Oncology 2025, 43: 571-571. DOI: 10.1200/jco.2025.43.5_suppl.571.
Investigation of ferroptosis and mTOR signaling in chromophobe renal cell carcinoma (ChRCC).Madsen K, Labaki C, Saad E, Alchoueiry M, Bi K, Hobeika C, Bakouny Z, Priolo C, Khabibullin D, Schindler N, Camp S, Saliby R, Heng D, Van Allen E, Shukla S, Henske E, Choueiri T, Braun D. Investigation of ferroptosis and mTOR signaling in chromophobe renal cell carcinoma (ChRCC). Journal Of Clinical Oncology 2025, 43: 583-583. DOI: 10.1200/jco.2025.43.5_suppl.583.
Association between PD-1 expression on tumor-infiltrating regulatory T cells and resistance to first-line nivolumab in advanced clear cell renal cell carcinoma: Insights from the HCRN GU16-260 clinical trial.Mohanna R, Simsek B, El Ahmar N, Jegede O, Matar S, Paul M, Nabil Laimon Y, Roberti De Oliveira G, Delcea A, Choueiri T, Braun D, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Wu C, McDermott D, Atkins M, Signoretti S. Association between PD-1 expression on tumor-infiltrating regulatory T cells and resistance to first-line nivolumab in advanced clear cell renal cell carcinoma: Insights from the HCRN GU16-260 clinical trial. Journal Of Clinical Oncology 2025, 43: 590-590. DOI: 10.1200/jco.2025.43.5_suppl.590.
Evaluating the therapeutic role of lymph node dissection in variant histology bladder cancer.Rahman S, Hesse D, Jalfon M, Kong V, Ghali F. Evaluating the therapeutic role of lymph node dissection in variant histology bladder cancer. Journal Of Clinical Oncology 2025, 43: 749-749. DOI: 10.1200/jco.2025.43.5_suppl.749.
Pilot study evaluating duplex sequencing of urinary DNA as a biomarker for recurrence in non-muscle invasive bladder cancer.Ghali F, Blaha O, Lam H, Kennedy S, Wright J. Pilot study evaluating duplex sequencing of urinary DNA as a biomarker for recurrence in non-muscle invasive bladder cancer. Journal Of Clinical Oncology 2025, 43: 865-865. DOI: 10.1200/jco.2025.43.5_suppl.865.
Comparative Performance of Machine Learning Models in Reducing Unnecessary Targeted Prostate BiopsiesChen F, Esmaili R, Khajir G, Zeevi T, Gross M, Leapman M, Sprenkle P, Justice A, Arora S, Weinreb J, Spektor M, Huber S, Humphrey P, Levi A, Staib L, Venkataraman R, Martin D, Onofrey J. Comparative Performance of Machine Learning Models in Reducing Unnecessary Targeted Prostate Biopsies. European Urology Oncology 2025 PMID: 39924390, DOI: 10.1016/j.euo.2025.01.005.
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing TherapiesAnnapureddy D, Taylor J, Kamat A, O'Donnell M, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y. Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies. European Urology Focus 2025 PMID: 39922753, DOI: 10.1016/j.euf.2025.01.001.
A neoantigen vaccine generates antitumour immunity in renal cell carcinomaBraun D, Moranzoni G, Chea V, McGregor B, Blass E, Tu C, Vanasse A, Forman C, Forman J, Afeyan A, Schindler N, Liu Y, Li S, Southard J, Chang S, Hirsch M, LeBoeuf N, Olive O, Mehndiratta A, Greenslade H, Shetty K, Klaeger S, Sarkizova S, Pedersen C, Mossanen M, Carulli I, Tarren A, Duke-Cohan J, Howard A, Iorgulescu J, Shim B, Simon J, Signoretti S, Aster J, Elagina L, Carr S, Leshchiner I, Getz G, Gabriel S, Hacohen N, Olsen L, Oliveira G, Neuberg D, Livak K, Shukla S, Fritsch E, Wu C, Keskin D, Ott P, Choueiri T. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 2025, 639: 474-482. PMID: 39910301, PMCID: PMC11903305, DOI: 10.1038/s41586-024-08507-5.
Editorial Comment.Honig S. Editorial Comment. Journal Of Urology 2025, 101097ju0000000000004426. PMID: 39878196, DOI: 10.1097/ju.0000000000004426.
Personalized frailty risk assessment in long-term survivors of colorectal cancer.Forman R, Westvold S, Long J, Fan J, Hyslop T, Yasin F, Conlin K, Jacobson S, Silber A, Wang S, Leapman M, Leeds I, Cecchini M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized frailty risk assessment in long-term survivors of colorectal cancer. Journal Of Clinical Oncology 2025, 43: 65-65. DOI: 10.1200/jco.2025.43.4_suppl.65.
A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer TypesBex A, Jewett M, Lewis B, Abel E, Albiges L, Berg S, Bratslavsky G, Braun D, Brugarolas J, Choueiri T, Finelli A, George D, Haas N, Hakimi A, Hammers H, Hirsch M, Jonasch E, Kapur P, Linehan W, Master V, McGregor B, McKay R, Mehra R, Pal S, Poteat S, Powles T, Rossi S, Shapiro D, Signoretti S, Singer E, Stravin C, Tannir N, Vaishampayan U, Xu W, Stewart G. A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types. European Urology 2025, 87: 385-389. PMID: 39855942, DOI: 10.1016/j.eururo.2025.01.007.
Telerehabilitation in patients with long COVID-19 syndromeLi S, Dong W, Dai B, Wang W, Tan W. Telerehabilitation in patients with long COVID-19 syndrome. European Journal Of Internal Medicine 2025 PMID: 39837753, DOI: 10.1016/j.ejim.2025.01.010.
Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomesXu W, Birch G, Meliki A, Moritz V, Bharadwaj M, Schindler N, Labaki C, Saliby R, Dinh K, Horst J, Sun M, Kashima S, Hugaboom M, Dighe A, Machaalani M, Lee G, Hurwitz M, McGregor B, Hirsch M, Shukla S, McDermott D, Signoretti S, Romee R, Choueiri T, Braun D. Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes. ESMO Open 2025, 10: 104105. PMID: 39813824, PMCID: PMC11783098, DOI: 10.1016/j.esmoop.2024.104105.
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinomaJammihal T, Saliby R, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, El Zarif T, El Ahmar N, Laimon Y, Eid M, Sheshdeh A, Krajewski K, Büttner F, Schwab M, Heng D, Casellas R, Rai K, Zacharias Millward N, Msaouel P, Karam J, Signoretti S, Van Allen E, Choueiri T, Braun D, Shukla S. Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Nature Cancer 2025, 6: 372-384. PMID: 39789182, DOI: 10.1038/s43018-024-00896-w.
Chapter 48 Multicenter considerationsPassarelli R, Sterling J, Singer E, Kim I. Chapter 48 Multicenter considerations. 2025, 245-248. DOI: 10.1016/b978-0-323-90186-4.00029-8.
Ethnic and Racial Social Identity, Socioeconomic Position, and Women’s Bladder HealthBrady S, Klusaritz H, Falke C, Gahagan S, Hebert-Beirne J, Hortsch S, Kenton K, Lewis C, Lipman T, McGwin G, Nodora J, Norton J, Nuscis K, Rodriguez-Ponciano D, Rudser K, Sutcliffe S, Wilson-Powers E, Cunningham S, Consortium P, Acevedo-Alvarez M, Fitzgerald C, Hardacker C, Hebert-Beirne J, Investigators M, Griffith J, Kenton K, Simon M, Brubaker L, Mueller E, Investigators, Brown O, Geynisman-Tan J, Mueller M, Markland A, Vaughan C, Burgio K, Coyne-Beasley T, Lewis C, McGwin G, Williams B, Lukacz E, LaCoursiere D, Gahagan S, Nodora J, Low L, Miller J, Smith A, Investigator, McGwin G, Rudser K, Brady S, Fok C, Harlow B, Rockwood T, Scal P, Newman D, Smith A, Berry A, Bilger A, Klusaritz H, Lipman T, Stapleton A, Wyman J, Sutcliffe S, James A, Lowder J, Meister M, Rickey L, Camenga D, Cunningham S, Chair S, Brubaker L, Office N. Ethnic and Racial Social Identity, Socioeconomic Position, and Women’s Bladder Health. Social Science & Medicine 2025, 117694. DOI: 10.1016/j.socscimed.2025.117694.

2024

Risks of grade reclassification among patients with Gleason grade group 1 prostate cancer and PI-RADS 5 findings on prostate MRISundaresan V, Webb L, Rabil M, Golos A, Sutherland R, Bailey J, Rajwa P, Seibert T, Loeb S, Cooperberg M, Catalona W, Sprenkle P, Kim I, Leapman M. Risks of grade reclassification among patients with Gleason grade group 1 prostate cancer and PI-RADS 5 findings on prostate MRI. Urologic Oncology Seminars And Original Investigations 2024, 43: 193.e19-193.e26. PMID: 39706698, DOI: 10.1016/j.urolonc.2024.11.007.
Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020Ajjawi I, Loeb S, Cooperberg M, Catalona W, Gross C, Ma X, Leapman M. Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020. JAMA 2024, 332: 2033-2036. PMID: 39565605, PMCID: PMC11579888, DOI: 10.1001/jama.2024.20580.
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder CancerTaylor J, Kamat A, Annapureddy D, Khene Z, Howard J, Tan W, McElree I, Facundo D, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y, O'Donnell M. Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer. European Urology Oncology 2024, 8: 469-476. PMID: 39694798, DOI: 10.1016/j.euo.2024.12.005.
An Infant With DHX37 Variant: A Novel Etiology of 46,XY DSD and Literature ReviewYilmaz R, Hittelman A, Vash-Margita A, Dinauer C, Weinzimer S, Gujral J. An Infant With DHX37 Variant: A Novel Etiology of 46,XY DSD and Literature Review. JCEM Case Reports 2024, 3: luae239. PMID: 39726663, PMCID: PMC11669865, DOI: 10.1210/jcemcr/luae239.
Artificial Intelligence–Driven Patient Selection for Preoperative Portal Vein Embolization for Patients with Colorectal Cancer Liver MetastasesKuhn T, Engelhardt W, Kahl V, Alkukhun A, Gross M, Iseke S, Onofrey J, Covey A, Camacho J, Kawaguchi Y, Hasegawa K, Odisio B, Vauthey J, Antoch G, Chapiro J, Madoff D. Artificial Intelligence–Driven Patient Selection for Preoperative Portal Vein Embolization for Patients with Colorectal Cancer Liver Metastases. Journal Of Vascular And Interventional Radiology 2024, 36: 477-488. PMID: 39638087, DOI: 10.1016/j.jvir.2024.11.025.
Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinomaSchoenfeld D, Djureinovic D, Su D, Zhang L, Lu B, Kamga L, Mann J, Huck J, Hurwitz M, Braun D, Jilaveanu L, Ring A, Kluger H. Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma. JCI Insight 2024, 10: e184545. PMID: 39561007, PMCID: PMC11721305, DOI: 10.1172/jci.insight.184545.
CT-Less Whole-Body Bone Segmentation of PET Images Using a Multimodal Deep Learning NetworkBao N, Zhang J, Li Z, Wei S, Zhang J, Greenwald S, Onofrey J, Lu Y, Xu L. CT-Less Whole-Body Bone Segmentation of PET Images Using a Multimodal Deep Learning Network. IEEE Journal Of Biomedical And Health Informatics 2024, 29: 1151-1164. PMID: 40030243, DOI: 10.1109/jbhi.2024.3501386.
MRI after focal therapy for prostate cancer: what radiologists must know?Jalilianhasanpour R, Arora S, Mansoori B, Raman S, Greenwood B, Sprenkle P, Schade G, Camacho M, Hosseini N, Westphalen A. MRI after focal therapy for prostate cancer: what radiologists must know? Abdominal Radiology 2024, 1-20. PMID: 39542951, DOI: 10.1007/s00261-024-04670-5.
Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumorsCosta P, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Coelho P, Campoverde L, Hardy N, Bialick S, Freire A, D’Amato G, Chang Y, Mesenger J, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors. Cancer 2024, 131: e35647. PMID: 39543805, DOI: 10.1002/cncr.35647.
Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsyLokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Sutherland R, Brito J, Renzulli J, Sprenkle P, Leapman M. Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy. Urologic Oncology Seminars And Original Investigations 2024 PMID: 39521675, DOI: 10.1016/j.urolonc.2024.10.018.
Construction and performance of a clinical prediction rule for ureteral stone without the use of race or ethnicity: A new STONE scoreMoore C, Gross C, Hart L, Molinaro A, Rhodes D, Singh D, Baloescu C. Construction and performance of a clinical prediction rule for ureteral stone without the use of race or ethnicity: A new STONE score. Journal Of The American College Of Emergency Physicians Open 2024, 5: e13324. PMID: 39524039, PMCID: PMC11543628, DOI: 10.1002/emp2.13324.
Bias in medical AI: Implications for clinical decision-makingCross J, Choma M, Onofrey J. Bias in medical AI: Implications for clinical decision-making. PLOS Digital Health 2024, 3: e0000651. PMID: 39509461, PMCID: PMC11542778, DOI: 10.1371/journal.pdig.0000651.
582 Spatial profiling reveals architecture difference between primary and lung metastatic ccRCCWang Y, Cho J, Laimon Y, Sheshdeh A, Murugan N, Yuan H, Wee J, Xu W, Braun D, Choueiri T, Wu C, Signoretti S, Freeman G, Hemberg M, Marasco W. 582 Spatial profiling reveals architecture difference between primary and lung metastatic ccRCC. 2024, a662-a662. DOI: 10.1136/jitc-2024-sitc2024.0582.
662 A phase1 study of autologous engineered CD4+ and CD8+ T cells, HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor and a FAS41BB switch receptor in patients with solid tumorsMitchell S, Khan B, Payumo F, Gabriela Chiorean E, Gahvari Z, Randolph Hecht J, Hurwitz M, Leidner R, Lenz H, Pelster M, Schoenfeld A, Punekar S, Zhao D, Basu S, Nagorsen D. 662 A phase1 study of autologous engineered CD4+ and CD8+ T cells, HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor and a FAS41BB switch receptor in patients with solid tumors. 2024, a759-a759. DOI: 10.1136/jitc-2024-sitc2024.0662.
Data-driven non-rigid motion detection and correction for NeuroEXPLORERZhang J, Sun C, Volpi T, Zeng T, Fontaine K, Du Y, Toyonaga T, Onofrey J, Lu Y, Carson R. Data-driven non-rigid motion detection and correction for NeuroEXPLORER. 2024, 00: 1-2. DOI: 10.1109/nss/mic/rtsd57108.2024.10658289.
Management strategies for radio-recurrent prostate cancer: a comprehensive reviewRahman S, Kim H, Webb L, Diaz G, Leapman M, Sprenkle P, Brito J, Renzulli J, Martin T, Kenney P, Kim I. Management strategies for radio-recurrent prostate cancer: a comprehensive review. Translational Cancer Research 2024, 0: 0-0. PMID: 39697737, PMCID: PMC11651831, DOI: 10.21037/tcr-24-245.
County-level racial disparities in prostate cancer–specific mortality from 2005 to 2020Washington S, Fakunle M, Wang L, Braun A, Leapman M, Cowan J, Cooperberg M. County-level racial disparities in prostate cancer–specific mortality from 2005 to 2020. JNCI Cancer Spectrum 2024, 8: pkae109. PMID: 39495143, PMCID: PMC11631307, DOI: 10.1093/jncics/pkae109.
Feasibility of Pay for Performance and Transparency Interventions on the Selection and Quality of Observational Management for Patients With Low-Risk Prostate Cancer in the Community PracticeGaylis F, Leapman M, Ellis S, Hu S, Cooperberg M, Loeb S, Chen R, Cohen E, Dato P, Aynehchi S, David R, Topp R, Santomauro B, Ginsburg K, Catalona W. Feasibility of Pay for Performance and Transparency Interventions on the Selection and Quality of Observational Management for Patients With Low-Risk Prostate Cancer in the Community Practice. Urology Practice 2024, 12: 241-248. PMID: 39453985, DOI: 10.1097/upj.0000000000000745.
Single‑center, retrospective, evaluator‑blinded, pilot and pivotal clinical trials: Assessing the mirCaP Kit (hsv2‑miR‑H9/hsa‑miR‑3659) as a diagnostic marker for prostate cancer in patients with PSA levels in the gray zoneKim W, Kim K, Kang H, Byun Y, Piao X, Kim Y, Lee S, Yun S, Ha Y, Kim J, Kim I. Single‑center, retrospective, evaluator‑blinded, pilot and pivotal clinical trials: Assessing the mirCaP Kit (hsv2‑miR‑H9/hsa‑miR‑3659) as a diagnostic marker for prostate cancer in patients with PSA levels in the gray zone. Oncology Letters 2024, 29: 23. PMID: 39512501, PMCID: PMC11542165, DOI: 10.3892/ol.2024.14770.
Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap?Smani S, Jalfon M, Sundaresan V, Lokeshwar S, Nguyen J, Halstuch D, Khajir G, Cavallo J, Sprenkle P, Leapman M, Kim I. Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap? Urologic Oncology Seminars And Original Investigations 2024 PMID: 39438211, DOI: 10.1016/j.urolonc.2024.10.002.
Aging-dependent loss of functional connectivity in a mouse model of Alzheimer’s disease and reversal by mGluR5 modulatorMandino F, Shen X, Desrosiers-Grégoire G, O’Connor D, Mukherjee B, Owens A, Qu A, Onofrey J, Papademetris X, Chakravarty M, Strittmatter S, Lake E. Aging-dependent loss of functional connectivity in a mouse model of Alzheimer’s disease and reversal by mGluR5 modulator. Molecular Psychiatry 2024, 1-16. PMID: 39424929, DOI: 10.1038/s41380-024-02779-z.
Molecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic ReviewFazekas T, Pallauf M, Kufel J, Miszczyk M, Tsuboi I, Matsukawa A, Laukhtina E, Kardoust Parizi M, Mancon S, Cadenar A, Schulz R, Yanagisawa T, Baboudjian M, Szarvas T, Gandaglia G, Tilki D, Nyirády P, Rajwa P, Leapman M, Shariat S. Molecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review. European Urology Oncology 2024 PMID: 39414421, DOI: 10.1016/j.euo.2024.09.017.
Trastuzumab Deruxtecan With Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 StudyHamilton E, Galsky M, Ochsenreither S, Del Conte G, Martín M, De Miguel M, Yu E, Williams A, Gion M, Tan A, Agrawal L, Rutten A, Machiels J, Cresta S, Debruyne P, Hennequin A, Moreno V, Minchom A, Valdes-Albini F, Petrylak D, Li L, Tsuchihashi Z, Suto F, Cheng F, Kandil M, Barrios D, Hurvitz S. Trastuzumab Deruxtecan With Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study. Clinical Cancer Research 2024, 30: 5548-5558. PMID: 39405343, PMCID: PMC11647201, DOI: 10.1158/1078-0432.ccr-24-1513.
Bladder Health Knowledge, Attitudes, and Beliefs among US Adolescent WomenCamenga D, Brady S, Bilger A, Klusaritz H, Lipman T, Levin E, Brown O, Cunningham S, LaCoursiere D, James A, Gahagan S, Hebert-Beirne J, Low L, Consortium P, Brubaker L, Mueller E, Acevedo-Alvarez M, Fitzgerald C, Hardacker C, Hebert-Beirne J, Griffith J, Kenton K, Simon M, Brown O, Geynisman-Tan J, Mueller M, Markland A, Vaughan C, Coyne-Beasley T, Burgio K, Lewis C, McGwin G, Williams B, Lukacz E, LaCoursiere D, Gahagan S, Nodora J, Low L, Miller J, Smith A, McGwin G, Rudser K, Brady S, Fok C, Harlow B, Scal P, Rockwood T, Newman D, Smith A, Berry A, Bilger A, Lipman T, Klusaritz H, Stapleton A, Wyman J, Sutcliffe S, James A, Lowder J, Meister M, Rickey L, Camenga D, Cunningham S, Brubaker L, Bethesda, Norton J. Bladder Health Knowledge, Attitudes, and Beliefs among US Adolescent Women. Journal Of Pediatric And Adolescent Gynecology 2024, 38: 60-67. PMID: 39374689, PMCID: PMC11769763, DOI: 10.1016/j.jpag.2024.09.008.
Implementation of a Urologic Surgery Skills Fair for Medical StudentsSmani S, Gardezi M, Laditi F, Sundaresan V, Kong V, Olawoyin O, Casilla-Lennon M. Implementation of a Urologic Surgery Skills Fair for Medical Students. Journal Of Surgical Education 2024, 81: 103300. PMID: 39368323, DOI: 10.1016/j.jsurg.2024.103300.
Editorial Comment on "Hypospadias Reconstruction Training: Development of an Ex-Vivo Model and Objective Evaluation of Surgical Skills".Bortnick EM. Editorial Comment on "Hypospadias Reconstruction Training: Development of an Ex-Vivo Model and Objective Evaluation of Surgical Skills". Urology 2024 PMID: 39362370, DOI: 10.1016/j.urology.2024.09.055.
241 - BLADDER HEALTH IN WOMEN: POPULATION-BASED ESTIMATES FROM THE US-BASED RISE FOR HEALTH STUDYSutcliffe S, Falke C, Rudser K, McGwin G, Brady S, Brubaker L, Kenton K, LaCoursiere D, Lewis C, Low L, Lowder J, Lukacz E, Mueller E, Newman D, Nodora J, Markland A, Putnam S, Rickey L, Rockwood T, Simon M, Stapleton A, Vaughan C, Wyman J, Smith A. 241 - BLADDER HEALTH IN WOMEN: POPULATION-BASED ESTIMATES FROM THE US-BASED RISE FOR HEALTH STUDY. Continence 2024, 12: 101583. DOI: 10.1016/j.cont.2024.101583.
POSTHUMOUS SPERM RETRIEVAL: SURVEY OF KNOWLEDGE OF INTENSIVE CARE UNIT PROVIDERSHayden C, Kong V, Honig S, Rotker K. POSTHUMOUS SPERM RETRIEVAL: SURVEY OF KNOWLEDGE OF INTENSIVE CARE UNIT PROVIDERS. Fertility And Sterility 2024, 122: e318. DOI: 10.1016/j.fertnstert.2024.07.965.
TRENDS IN POST VASECTOMY SEMEN ANALYSIS (PVSA) UTILIZATION PRE- AND POST-DOBBS V JACKSON: DATA FROM A LIBERAL-LEANING STATEAyaz A, Rotker K, Seli E, Honig S. TRENDS IN POST VASECTOMY SEMEN ANALYSIS (PVSA) UTILIZATION PRE- AND POST-DOBBS V JACKSON: DATA FROM A LIBERAL-LEANING STATE. Fertility And Sterility 2024, 122: e375-e376. DOI: 10.1016/j.fertnstert.2024.08.158.
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate CancerKunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, PMCID: PMC11581571, DOI: 10.1001/jamanetworkopen.2024.40591.
A Flow-based Truncated Denoising Diffusion Model for super-resolution Magnetic Resonance Spectroscopic ImagingDong S, Cai Z, Hangel G, Bogner W, Widhalm G, Huang Y, Liang Q, You C, Kumaragamage C, Fulbright R, Mahajan A, Karbasi A, Onofrey J, de Graaf R, Duncan J. A Flow-based Truncated Denoising Diffusion Model for super-resolution Magnetic Resonance Spectroscopic Imaging. Medical Image Analysis 2024, 99: 103358. PMID: 39353335, PMCID: PMC11609020, DOI: 10.1016/j.media.2024.103358.
Preventing the Next Neglected Pessary: A Quality Improvement Initiative.Popiel P, Maggi M, Dalal S, Curran M, Rickey L. Preventing the Next Neglected Pessary: A Quality Improvement Initiative. Urogynecology 2024 PMID: 39331811, DOI: 10.1097/spv.0000000000001578.
Sociodemographic disparities in prostate cancer imagingSundaresan V, Lokeshwar S, Sutherland R, Sohoni N, Golos A, Ajjawi I, Leapman M. Sociodemographic disparities in prostate cancer imaging. Abdominal Radiology 2024, 1-9. PMID: 39325212, DOI: 10.1007/s00261-024-04603-2.
Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsyPress B, Lokeshwar S, Webb L, Khajir G, Smani S, Olawoyin O, Gardezi M, Rahman S, Leapman M, Sprenkle P. Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 1168-1176. PMID: 39465014, PMCID: PMC11502073, DOI: 10.37349/etat.2024.00269.
Rechallenging with anti-PD-1 therapy in advanced renal cell carcinomaYochum Z, Braun D. Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma. The Lancet 2024, 404: 1280-1282. PMID: 39284326, DOI: 10.1016/s0140-6736(24)01866-x.
Reliability of Uroflowmetry Pattern Interpretation in Adult WomenRickey L, Mueller E, Newman D, Markland A, Falke C, Rudser K, Smith A, Mueller M, Lowder J, Lukacz E, Consortium P. Reliability of Uroflowmetry Pattern Interpretation in Adult Women. Neurourology And Urodynamics 2024, 43: 2084-2092. PMID: 39264028, DOI: 10.1002/nau.25584.
Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1.Rodarte K, Nir Heyman S, Guo L, Flores L, Savage T, Villarreal J, Deng S, Xu L, Shah R, Oliver T, Johnson J. Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1. Cancer Research 2024, 84: 3522-3537. PMID: 39264686, PMCID: PMC11534540, DOI: 10.1158/0008-5472.can-24-1388.
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell CarcinomaBarata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason G, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Lerner S, Balzer-Haas N, Pal S. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal Of Clinical Oncology 2024, 42: 3911-3916. PMID: 39255440, PMCID: PMC11575905, DOI: 10.1200/jco.24.00767.
Mapping cellular interactions from spatially resolved transcriptomics dataZhu J, Wang Y, Chang W, Malewska A, Napolitano F, Gahan J, Unni N, Zhao M, Yuan R, Wu F, Yue L, Guo L, Zhao Z, Chen D, Hannan R, Zhang S, Xiao G, Mu P, Hanker A, Strand D, Arteaga C, Desai N, Wang X, Xie Y, Wang T. Mapping cellular interactions from spatially resolved transcriptomics data. Nature Methods 2024, 21: 1830-1842. PMID: 39227721, DOI: 10.1038/s41592-024-02408-1.
Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncologyFigiel S, Bates A, Braun D, Eapen R, Eckstein M, Manley B, Milowsky M, Mitchell T, Bryant R, Sfakianos J, Lamb A. Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology. European Urology 2024, 87: 8-14. PMID: 39227262, DOI: 10.1016/j.eururo.2024.08.025.
1622P A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-upAggarwal R, Tagawa S, Monk P, Zhu X, Jones R, Linch M, Costin D, de Bono J, Karsh L, Petrylak D, Borderies P, Deshpande R, O'Neill V, Zhang J. 1622P A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up. Annals Of Oncology 2024, 35: s979. DOI: 10.1016/j.annonc.2024.08.1703.
1968P Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)Rosenberg J, Petrylak D, Flaig T, Hoimes C, Gupta S, O'Donnell P, Mar N, Friedlander T, Tagawa S, Bilen M, Brown J, McKay R, Merchan J, Srinivas S, Shetty A, Moreno B, Davis G, Wirtz H, Zhu Y, Milowsky M. 1968P Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC). Annals Of Oncology 2024, 35: s1139-s1140. DOI: 10.1016/j.annonc.2024.08.2053.
176P ERBB2 amplifications across sex, race, and cancer typesMachaalani M, Chehade R, Nassar A, Zarif T, Saad E, Yekeduz E, Saliby R, Steiner C, Nawfal R, Semaan K, Eid M, Lee G, Pomerantz M, McKay R, Tarantino P, Braun D, Sun M, Tolaney S, Choueiri T. 176P ERBB2 amplifications across sex, race, and cancer types. Annals Of Oncology 2024, 35: s285-s286. DOI: 10.1016/j.annonc.2024.08.2181.
1702P Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)McGregor B, Paul M, Xie W, Xu W, Bilen M, Braun D, Berg S, Zhang T, McKay R, McDermott D, Hammers H, Choueiri T. 1702P Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh). Annals Of Oncology 2024, 35: s1020. DOI: 10.1016/j.annonc.2024.08.1795.
1705P Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimensNawfal R, Semaan K, Eid M, Paul M, Saliby R, Chehade R, Machaalani M, Saad E, Phillips N, Canniff J, Vasseur D, Zarif T, Yekeduz E, Sun M, Baca S, Braun D, Xie W, Krajewski K, Choueiri T. 1705P Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens. Annals Of Oncology 2024, 35: s1022-s1023. DOI: 10.1016/j.annonc.2024.08.1798.
1694MO Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): Analysis from CheckMate 9ERBraun D, Wang Y, Yu A, Pickering C, Serie D, Choueiri T, Xu W, Sun M, Vemula S, Gupta S. 1694MO Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): Analysis from CheckMate 9ER. Annals Of Oncology 2024, 35: s1012-s1013. DOI: 10.1016/j.annonc.2024.08.1787.
1704P Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) studySaliby R, Xie W, Wells J, Saad E, Eid M, Semaan K, Labaki C, Ferrier E, Zarba M, Ebrahimi H, Rodriguez C, Ruiz J, Powles T, Wood L, De Velasco Oria G, Takemura K, Braun D, Heng D, Choueiri T. 1704P Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study. Annals Of Oncology 2024, 35: s1021-s1022. DOI: 10.1016/j.annonc.2024.08.1797.
Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional SeriesRahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series. Cancers 2024, 16: 3050. PMID: 39272908, PMCID: PMC11394101, DOI: 10.3390/cancers16173050.
Assessing the safety of ureteral stent placement for obstructive urolithiasis in patients during the COVID-19 pandemicChoksi A, Lokeshwar S, Gardezi M, Hayden C, Khan A, Tran T, Singh D, Motamedinia P, Martin T. Assessing the safety of ureteral stent placement for obstructive urolithiasis in patients during the COVID-19 pandemic. Translational Andrology And Urology 2024, 13: 1814822-1811822. PMID: 39434763, PMCID: PMC11491224, DOI: 10.21037/tau-24-57.
Targeting TREX1 induces innate immune response in drug-resistant Small Cell Lung CancerMurayama T, Mahadevan N, Meador C, Ivanova E, Pan Y, Knelson E, Tani T, Nakayama J, Ma X, Thai T, Hung Y, Kim W, Watanabe H, Cai K, Hata A, Paweletz C, Barbie D, Cañadas I. Targeting TREX1 induces innate immune response in drug-resistant Small Cell Lung Cancer. Cancer Research Communications 2024, 4: 2399-2414. PMID: 39177280, PMCID: PMC11391691, DOI: 10.1158/2767-9764.crc-24-0360.
Reply to Editorial Comment on “Association of Crowd-Sourced Assessment of Technical Skills and Outcomes of Robotic-assisted Radical Prostatectomy”Rabil M, Leapman M, Cavallo J. Reply to Editorial Comment on “Association of Crowd-Sourced Assessment of Technical Skills and Outcomes of Robotic-assisted Radical Prostatectomy”. Urology 2024, 193: 97-98. PMID: 39208938, DOI: 10.1016/j.urology.2024.08.054.
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor TherapyPetrylak D, Tagawa S, Jain R, Bupathi M, Balar A, Kalebasty A, George S, Palmbos P, Nordquist L, Davis N, Ramamurthy C, Sternberg C, Loriot Y, Agarwal N, Park C, Tonelli J, Vance M, Zhou H, Grivas P, Petrylak D, Tagawa S, Jain R, Bupathi M, Balar A, Kalebasty A, George S, Palmbos P, Nordquist L, Davis N, Ramamurthy C, Sternberg C, Agarwal N, Park C, Tonelli J, Vance M, Zhou H, Grivas P, Loriot Y. TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy. Journal Of Clinical Oncology 2024, 42: 3410-3420. PMID: 39186707, PMCID: PMC11458109, DOI: 10.1200/jco.23.01720.
Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancerTaylor J, Kamat A, O'Donnell M, Annapureddy D, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y. Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer. BJU International 2024, 135: 260-268. PMID: 39183466, PMCID: PMC11745998, DOI: 10.1111/bju.16509.
Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient SelectionLi R, Hensley P, Gupta S, Al-Ahmadie H, Babjuk M, Black P, Brausi M, Bree K, Fernández M, Guo C, Horowitz A, Lamm D, Lerner S, Lotan Y, Mariappan P, McConkey D, Mertens L, Mir C, Ross J, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess P, Svatek R, Tan W, Taoka R, Buckley R, Kamat A. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. European Urology 2024, 86: 516-527. PMID: 39183090, DOI: 10.1016/j.eururo.2024.08.001.

Download Full List